Decreased muscle mass and function,also known as sarcopenia,is common in patients with cirrhosis and is associated with a poor prognosis.Although the pathogenesis of this disorder has not been fully elucidated,a disor...Decreased muscle mass and function,also known as sarcopenia,is common in patients with cirrhosis and is associated with a poor prognosis.Although the pathogenesis of this disorder has not been fully elucidated,a disordered gutmuscle axis probably plays an important role.Decreased barrier function of the gut and liver,gut dysbiosis,and small intestinal bacterial overgrowth(SIBO)can lead to increased blood levels of ammonia,lipopolysaccharides,pro-inflammatory mediators,and myostatin.These factors have complex negative effects on muscle mass and function.Drug interventions that target the gut microbiota(long-term use of rifaximin,lactulose,lactitol,or probiotics)positively affect most links of the compromised gut-muscle axis in patients with cirrhosis by decreasing the levels of hyperammonemia,bacterial translocation,and systemic inflammation and correcting gut dysbiosis and SIBO.However,although these drugs are promising,they have not yet been investigated in randomized controlled trials specifically for the treatment and prevention of sarcopenia in patients with cirrhosis.No data exist on the effects of fecal transplantation on most links of gut-muscle axis in cirrhosis;however,the results of animal experimental studies are promising.展开更多
Small intestinal bacterial overgrowth(SIBO)is defined as an increase in the bacterial content of the small intestine above normal values.The presence of SIBO is detected in 33.8%of patients with gastroenterological co...Small intestinal bacterial overgrowth(SIBO)is defined as an increase in the bacterial content of the small intestine above normal values.The presence of SIBO is detected in 33.8%of patients with gastroenterological complaints who underwent a breath test,and is significantly associated with smoking,bloating,abdominal pain,and anemia.Proton pump inhibitor therapy is a significant risk factor for SIBO.The risk of SIBO increases with age and does not depend on gender or race.SIBO complicates the course of a number of diseases and may be of pathogenetic significance in the development of their symptoms.SIBO is significantly associated with functional dyspepsia,irritable bowel syndrome,functional abdominal bloating,functional constipation,functional diarrhea,short bowel syndrome,chronic intestinal pseudo-obstruction,lactase deficiency,diverticular and celiac diseases,ulcerative colitis,Crohn’s disease,cirrhosis,metabolic-associated fatty liver disease(MAFLD),primary biliary cholangitis,gastroparesis,pancreatitis,cystic fibrosis,gallstone disease,diabetes,hypothyroidism,hyperlipidemia,acromegaly,multiple sclerosis,autism,Parkinson’s disease,systemic sclerosis,spondylarthropathy,fibromyalgia,asthma,heart failure,and other diseases.The development of SIBO is often associated with a slowdown in orocecal transit time that decreases the normal clearance of bacteria from the small intestine.The slowdown of this transit may be due to motor dysfunction of the intestine in diseases of the gut,autonomic diabetic polyneuropathy,and portal hypertension,or a decrease in the motor-stimulating influence of thyroid hormones.In a number of diseases,including cirrhosis,MAFLD,diabetes,and pancreatitis,an association was found between disease severity and the presence of SIBO.Further work on the effect of SIBO eradication on the condition and prognosis of patients with various diseases is required.展开更多
文摘Decreased muscle mass and function,also known as sarcopenia,is common in patients with cirrhosis and is associated with a poor prognosis.Although the pathogenesis of this disorder has not been fully elucidated,a disordered gutmuscle axis probably plays an important role.Decreased barrier function of the gut and liver,gut dysbiosis,and small intestinal bacterial overgrowth(SIBO)can lead to increased blood levels of ammonia,lipopolysaccharides,pro-inflammatory mediators,and myostatin.These factors have complex negative effects on muscle mass and function.Drug interventions that target the gut microbiota(long-term use of rifaximin,lactulose,lactitol,or probiotics)positively affect most links of the compromised gut-muscle axis in patients with cirrhosis by decreasing the levels of hyperammonemia,bacterial translocation,and systemic inflammation and correcting gut dysbiosis and SIBO.However,although these drugs are promising,they have not yet been investigated in randomized controlled trials specifically for the treatment and prevention of sarcopenia in patients with cirrhosis.No data exist on the effects of fecal transplantation on most links of gut-muscle axis in cirrhosis;however,the results of animal experimental studies are promising.
文摘Small intestinal bacterial overgrowth(SIBO)is defined as an increase in the bacterial content of the small intestine above normal values.The presence of SIBO is detected in 33.8%of patients with gastroenterological complaints who underwent a breath test,and is significantly associated with smoking,bloating,abdominal pain,and anemia.Proton pump inhibitor therapy is a significant risk factor for SIBO.The risk of SIBO increases with age and does not depend on gender or race.SIBO complicates the course of a number of diseases and may be of pathogenetic significance in the development of their symptoms.SIBO is significantly associated with functional dyspepsia,irritable bowel syndrome,functional abdominal bloating,functional constipation,functional diarrhea,short bowel syndrome,chronic intestinal pseudo-obstruction,lactase deficiency,diverticular and celiac diseases,ulcerative colitis,Crohn’s disease,cirrhosis,metabolic-associated fatty liver disease(MAFLD),primary biliary cholangitis,gastroparesis,pancreatitis,cystic fibrosis,gallstone disease,diabetes,hypothyroidism,hyperlipidemia,acromegaly,multiple sclerosis,autism,Parkinson’s disease,systemic sclerosis,spondylarthropathy,fibromyalgia,asthma,heart failure,and other diseases.The development of SIBO is often associated with a slowdown in orocecal transit time that decreases the normal clearance of bacteria from the small intestine.The slowdown of this transit may be due to motor dysfunction of the intestine in diseases of the gut,autonomic diabetic polyneuropathy,and portal hypertension,or a decrease in the motor-stimulating influence of thyroid hormones.In a number of diseases,including cirrhosis,MAFLD,diabetes,and pancreatitis,an association was found between disease severity and the presence of SIBO.Further work on the effect of SIBO eradication on the condition and prognosis of patients with various diseases is required.